Introduction
============

Cervical cancer (CC) is still a serious public health problem worldwide. Although there have been advances in screening and early diagnostic methods in recent years ([@ref-11]), more than 85% of cases and deaths are in the developing countries ([@ref-10]). The 5-year survival rate of advanced-stage patients also remains below 40% and the poor prognosis of CC is a serious problem facing these patients ([@ref-18]). Early diagnosis and prediction of outcomes is an effective method to improve the prognosis of CC. However, molecular markers that can predict the prognosis of CC remain unknown. Thus, there is an urgent need to identify effective biomarkers that predict the survival of patients with CC.

Long non-coding RNAs (lncRNAs) are non-coding RNAs with a length of more than 200 nucleotides, which are widely present in the genome and can regulate gene expression ([@ref-5]; [@ref-7]; [@ref-16]). They are involved in the development of various cancers and diseases. Increasing evidence suggests that different cancer types have different lncRNAs differentially expressed in tumor tissue ([@ref-23]; [@ref-32]), including CC ([@ref-9]). At present, many studies have reported that lncRNAs can be used as biomarkers for the diagnosis of CC. For example, lncRNA expression has been characterized in early CC ([@ref-19]), and the lncRNA RNAPVT1 may be a novel biomarker for early noninvasive diagnosis of CC ([@ref-26]). However, only a few studies have reported lncRNAs as biomarkers for overall survival (OS) of CC.

The Cancer Genome Atlas (TCGA) database has provided an application platform of large-sample-size genome sequencing data for CC. Although a number of lncRNAs have been characterized and predict clinical diagnosis in CC, there are still conflicting results from previous studies. In the present study, lncRNA differential expression profiles were obtained and combined with clinical features from the TCGA database. We identified lncRNAs differentially expressed between CC tissues and normal cervical tissues by analyzing the high-throughput lncRNA sequencing data which were downloaded from TCGA database. In addition, we investigated the prognostic value of the differentially expressed lncRNAs. Through further analysis, we found a two-lncRNA signature that can effectively predict the prognosis of CC patients. This may lead to new therapeutic interventions in CC.

Materials and Methods
=====================

The Cancer Genome Atlas database and samples
--------------------------------------------

RNA sequencing data from 307 cases of cervical squamous cell carcinoma (CESC) was downloaded from the TCGA database (up to May 26, 2017, <https://portal.gdc.cancer.gov/>), including individuals with clinical information. The following patient or lncRNA exclusion criteria were applied: 1) no complete tissue samples were present for data analysis; 2) histologic diagnosis was not CESC; 3) other malignancies apart from CESC were present; 4) The differentially expressed lncRNAs which were present in no more than 10% of the samples were eliminated. Overall, 289 CC patients were included in the present study providing 289 CC tissue samples and three adjacent normal tissue samples. The clinical data included staging information and outcomes of CESC patients. Processing this data did not violate the requirements of TCGA's human protection and data access policies. (<http://cancergenome.nih.gov/publications/publicationguidelines>).

In addition, 31 CC patient tissue specimens (primary solid tumor and solid normal tissue) were collected from the Zhongda Hospital (Nanjing, China) of Southeast University, between 2016 and 2017, for qRT-PCR analysis. The tissues were snap-frozen in RNAlater (Ambion, Austin, TX, USA) after surgical resection and stored immediately in liquid nitrogen for subsequent total RNA extraction and analysis. These 31 patients (aged 23--64 years) were diagnosed with CC based on the histopathology and clinical history. All patients signed informed consent and this study was approved by the Zhongda Hospital Southeast University ethics committee.

Identification of differentially expressed lncRNAs
--------------------------------------------------

The TCGA database provides normalized count data for RNA sequencing through the RNASeqV2 system, including lncRNA and mRNA expression profiles. The CESC level 3 lncRNA sequencing raw data were obtained through Illumina HiSeq 2000 RNA sequencing platforms (Illumina Inc., Hayward, CA, USA). Data were already normalized by the TCGA. The data of tumor CC tissues were already normalized to the adjacent normal tissues. RNA-Seq expression level read counts are normalized using two related methods: The Fragments per Kilobase of transcript per Million mapped reads (FPKM) and The upper quartile FPKM (FPKM-UQ). The differentially expressed RNAs included those upregulated and downregulated with fold changes \>2 and \<0.5, respectively, and adjusted false discovery rate at *P* \< 0.05. To detect the differential expression of lncRNAs, samples were divided into three groups based on FIGO stage I, stage II and stages III--IV. The intersection of the lncRNAs was selected for further analysis. In addition, sequencing results of differentially expressed lncRNAs that showed no change in more than 10% of all samples were eliminated.

Identification of the specific lncRNA prognostic signature
----------------------------------------------------------

The expression level of each differentially expressed lncRNA was transformed by log2 to calculate the risk score. Subsequently, we further analyzed clinical features related to lncRNAs in CC. The univariate Cox proportional hazard model was used to analyze the effects of risk score and clinical features on the OS of CC patients ([@ref-2]; [@ref-6]). The multivariate Cox proportional hazard model was used to evaluate the prognostic value of these OS-related lncRNAs. Based on the previously reported risk score model ([@ref-30]), we constructed a prognosis-related risk score based on lncRNA expression levels. The formula is: Riskscore = explncRNA1 × β lncRNA1 + explncRNA2 × β lncRNA2+...+explncRNAn × β lncRNAn, where exp represents expression level and β represents the regression coefficient from the multivariate Cox regression model ([@ref-29]). We used the median as the cutoff point in risk score. The CC patients were divided into high- and low-risk score group, respectively ([@ref-33]). The receiver operating characteristic (ROC) curve analysis within 5 years was used to calculate the predictive value of the risk score for time-dependent outcomes ([@ref-8]).

qRT-PCR verification of specific lncRNA expression in CC tissues and ROC curve analysis
---------------------------------------------------------------------------------------

We used qRT-PCR to analyze actual expression levels and validate the accuracy and reliability of the two lncRNAs in 31 newly diagnosed CC patients. All results were normalized to the control reference gene GAPDH. Following the standardized manufacturer's protocol, total RNA was isolated from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA purity was determined using a NanoDrop 2000 spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). RT reactions and qRT-PCR were both conducted according to the manufacturer's protocol using the Reverse Transcription System and qPCR Master Mix kit (Promega, Madison, WI, USA), respectively. Step One Plus^TM^ PCR System (Applied Biosystems, Foster City, CA, USA) was used to detect the expression levels of lncRNAs. All the primers were produced by Generay Biotech Co., Ltd. (Shanghai, China). qRT-PCR results were calculated by the 2^−ΔΔCt^ method using the formulas ΔCt = Ct~ΔlncRNAs~ -- Ct~ΔGAPDH~ and ΔΔCt = ΔCt~tumor\ tissues~ -- ΔCt~adjacent\ non-tumor\ tissues~ ([@ref-22]). The ROC curve was used to evaluate the diagnostic value of the expression levels of the two lncRNAs. A *P* value of \<0.05 was considered statistically significant.

Cell culture and qRT-PCR verification of expression of two lncRNAs in cervical cancer cell lines
------------------------------------------------------------------------------------------------

Three human CC cell lines (Hela, SiHa and C33-a), and an immortalized human cervical epithelial cell line (H8) were purchased from Shanghai Chuyu Biological Co., Ltd. The cells were cultured in 5% CO~2~ humidified atmosphere at 37 °C, using high-glucose Dulbecco's modified Eagle's medium (HyClone, South Logan, UT, USA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 mg/mL streptomycin. qRT-PCR and total RNA extraction conditions, reagents and methods are the same as for tissues.

Statistical analysis
--------------------

Statistical analysis was performed by IBM SPSS Version 24.0. The final results are shown as means ± SD. Student's *t*-tests were used to compare two groups of sequencing data. In all cases, *P* value of \<0.05 was considered statistically significant. Fold change was used to analyze the statistical significance of results. Clinical parameters and risk scores were screened and compared using univariate and multivariate Cox regression models. In addition, based on the expression of lncRNA levels in CC patients, we performed ROC curve and area under curve (AUC) analyses to judge diagnostic value. R language was used as the main tool for generation of ROC curves ([@ref-34]).

Results
=======

Identification of significantly differentially expressed lncRNAs and clinical characteristics of patients
---------------------------------------------------------------------------------------------------------

There were 289 CC primary solid tumors and three solid normal tissues with clinical patient information obtained from TCGA which were included in the present study. The average age of patients was 47.31 ± 13.62 years. The OS time was 1045.70 ± 67.07 days, 71 patients died. Significant differentially expressed lncRNAs were identified based on the criteria of fold change \>2 and \<0.5 at *P* value \<0.05. According to inclusion--exclusion criteria, we obtained 49 differentially expressed lncRNAs included in the intersection of the three groups' analyzed results ([Fig. 1A](#fig-1){ref-type="fig"}; [Table 1](#table-1){ref-type="table"}). The available clinical features from the TCGA database are shown in [Table 2](#table-2){ref-type="table"}.

![Forty-nine differentially expressed lncRNAs between FIGO stage I/Normal, FIGO stage II/Normal, FIGO stages III--IV/Normal.\
(A) Venn diagrams showing the number of common lncRNAs differentially expressed in different FIGO stages. (B) and (C) Two differentially expressed lncRNAs (ILF3-AS1 and RASA4CP). Kaplan--Meier curves showing the relationship between the lncRNAs and overall survival. The cases were divided into under- and over-expression groups.](peerj-07-6761-g001){#fig-1}
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###### The common list of lncRNAs abnormally expressed in all FIGO stages in CECS.
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  lncRNA         Regulation   Fold-change[\*](#table-1fn1){ref-type="fn"}   *P*-value[\*](#table-1fn1){ref-type="fn"}
  -------------- ------------ --------------------------------------------- -------------------------------------------
  EMX2OS         Down         0.02                                          0.00000
  CARMN          Down         0.02                                          0.00000
  MIR4697HG      Down         0.04                                          0.00000
  MIR100HG       Down         0.06                                          0.00001
  MBNL1-AS1      Down         0.08                                          0.00000
  HOXA11-AS      Down         0.10                                          0.00044
  MEG3           Down         0.10                                          0.00020
  LINC01140      Down         0.10                                          0.00000
  LINC00341      Down         0.11                                          0.00000
  A2M-AS1        Down         0.11                                          0.00000
  TPTEP1         Down         0.12                                          0.00001
  MIR99AHG       Down         0.12                                          0.00004
  SERTAD4-AS1    Down         0.12                                          0.00004
  NR2F1-AS1      Down         0.13                                          0.00044
  SMIM10L2B      Down         0.16                                          0.00003
  LINC00663      Down         0.19                                          0.00003
  LINC00312      Down         0.21                                          0.00020
  EPB41L4A-AS1   Down         0.21                                          0.00001
  LINC00950      Down         0.25                                          0.00002
  SNHG7          Down         0.26                                          0.00012
  RASA4CP        Down         0.26                                          0.00004
  GTF2IRD2P1     Down         0.26                                          0.00008
  ATP1A1-AS1     Down         0.28                                          0.00012
  ST7-AS1        Down         0.28                                          0.00168
  ILF3-AS1       Down         0.30                                          0.00013
  LINC00936      Down         0.30                                          0.00083
  FAM66C         Down         0.30                                          0.00000
  LOH12CR2       Down         0.31                                          0.00000
  ACVR2B-AS1     Down         0.31                                          0.00033
  AMZ2P1         Down         0.32                                          0.00028
  FLJ10038       Down         0.33                                          0.00011
  ZNF876P        Down         0.36                                          0.00032
  FTX            Down         0.42                                          0.00137
  EEF1A1P9       Down         0.43                                          0.00011
  TOP1P1         Up           2.10                                          0.00062
  EP400NL        Up           2.51                                          0.00012
  LOC146880      Up           2.52                                          0.00014
  OIP5-AS1       Up           3.10                                          0.00000
  FBXO22-AS1     Up           3.71                                          0.00030
  GOLGA2P10      Up           4.12                                          0.00149
  GEMIN8P4       Up           4.72                                          0.00061
  ASMTL-AS1      Up           4.91                                          0.00028
  MST1P2         Up           5.21                                          0.00166
  DDX12P         Up           5.21                                          0.00000
  LINC00467      Up           5.74                                          0.00003
  CDKN2B-AS1     Up           6.40                                          0.00009
  GOLGA2P5       Up           6.69                                          0.00005
  TMPO-AS1       Up           7.28                                          0.00000
  MIR9-3HG       Up           49.93                                         0.00001

**Note:**

Fold change \>2 or \<0.5, and *P* \< 0.05.
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###### The available clinical characteristics of CESC cases and their relationship to overall survival.
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  Variables                          Patient   Univariate analysis      Multivariate analysis                                              
  ----------------- ---------------- --------- ------------------------ ----------------------------------------- ------------------------ -----------------------------------------
  Race              White            199       1 \[reference\]                                                                             
                    Black            27        0.97 \[0.46--2.05\]      0.930                                                              
                    Asian            27        1.06 \[0.38--2.96\]      0.910                                                              
                    Others           2         7.39 \[1--54.76\]        0.050[\*](#table-2fn2){ref-type="fn"}                              
  Age               \<45             130       1 \[reference\]                                                                             
                    ≥45              159       1.34 \[0.82--2.18\]      0.250                                                              
  BMI               Lean             12        1 \[reference\]                                                                             
                    Normal           80        0.66 \[0.23--1.95\]      0.460                                                              
                    Overweight       155       0.45 \[0.16--1.3\]       0.140                                                              
  HPV               Low              265       1 \[reference\]                                                                             
                    High             2         3.38 \[0.46--24.6\]      0.230                                                              
  Tobacco           Non-smoker       141       1 \[reference\]                                                                             
                    Current smoker   110       1.33 \[0.81--2.18\]      0.260                                                              
  Clinical stage    Stage i          159       1 \[reference\]                                                    1 \[reference\]          
                    Stage ii         68        0.81 \[0.41--1.6\]       0.550                                     1.66 \[0.77--3.58\]      0.196
                    Stage iii        44        1.28 \[0.63--2.58\]      0.490                                     0.39 \[0.39--4.53\]      0.648
                    Stage iv         18        4.41 \[2.33--8.32\]      \<0.001[\*](#table-2fn2){ref-type="fn"}   3.70 \[1.73--7.90\]      \<0.001[\*](#table-2fn2){ref-type="fn"}
  T stage           t1+t2            206       1 \[reference\]                                                                             
                    t3+t4+tx         43        3.58 \[2.01--6.35\]      \<0.001[\*](#table-2fn2){ref-type="fn"}                            
  N stage           n0               130       1 \[reference\]                                                                             
                    n1               57        0.25 \[0.13--0.5\]       \<0.001[\*](#table-2fn2){ref-type="fn"}                            
                    nx               62        0.71 \[0.36--1.38\]      0.310                                                              
  M stage           m0               112       1 \[reference\]                                                                             
                    m1               9         4.11 \[1.38--12.23\]     0.010[\*](#table-2fn2){ref-type="fn"}                              
                    mx               124       1.93 \[1.08--3.44\]      0.030[\*](#table-2fn2){ref-type="fn"}                              
  Neoplasm cancer   Tumor free       189       1 \[reference\]                                                    1 \[reference\]          
                    With tumor       78        21.27 \[11.11--40.72\]   \<0.001[\*](#table-2fn2){ref-type="fn"}   29.27 \[12.54--68.30\]   \<0.001[\*](#table-2fn2){ref-type="fn"}
  Menopause         Pre              121       1 \[reference\]                                                                             
                    Post             75        1.54 \[0.54--4.43\]      0.420                                                              
                    Peri             25        1.65 \[0.57--4.82\]      0.360                                                              
  RISK              Low              144       1 \[reference\]                                                    1 \[reference\]          
                    High             145       2.48 \[1.5--4.12\]       \<0.001[\*](#table-2fn2){ref-type="fn"}   2.60 \[1.42--4.95\]      0.002[\*](#table-2fn2){ref-type="fn"}

**Note:**

HR, hazard ratio; CI, confidence interval.

*P* \< 0.05.

Construction of an lncRNA signature significantly associated with prognostic features
-------------------------------------------------------------------------------------

The 49 differentially expressed specific lncRNAs were further analyzed. We analyzed race, age, body mass index, human papillomavirus, tobacco use, clinical stage, tumor-node-metastasis staging system, tumor status and menopause in the TCGA database. In the univariate Cox proportional hazard model, four of the 49 differential expressed lncRNAs had important prognostic value (*P* \< 0.05; [Table 3](#table-3){ref-type="table"}). Further analysis using multivariate Cox regression showed that only two lncRNAs were important and independent biomarkers for OS in CC patients: ILF3-AS1 and RASA4CP (*P* \< 0.05; [Table 3](#table-3){ref-type="table"}). These two specific lncRNAs were positively correlated with OS (log-rank *P* \< 0.05; [Figs. 1B](#fig-1){ref-type="fig"} and [1C](#fig-1){ref-type="fig"}). Using ROC curve analysis, the AUC values for ILF3-AS1 and RASA4CP were calculated as 0.963 and 0.988, respectively (*P* \< 0.05; [Fig. S1](#supp-2){ref-type="supplementary-material"}). The AUC of these two lncRNAs together was 0.991, which was higher than that of each lncRNA taken alone (*P* \< 0.05). We next built a risk score for predicting the prognostic value. The formula was Risk score = expILF3-AS1 × (−0.703) + expRASA4CP × (−0.576). The 289 patients were divided into low-risk (*n* = 144) and high-risk (*n* = 145) groups ([Fig. 2](#fig-2){ref-type="fig"}). The survival time of patients in the low-risk score group was 1152.48 ± 104.27 days compared to 939.66 ± 83.98 days in the high-risk score group. The risk score largely predicted 5-year survival of CC patients, as the AUC upon ROC curve analysis was 0.607 ([Fig. 3A](#fig-3){ref-type="fig"}). Furthermore, Kaplan--Meier curves showed that low-risk group was positively correlated with OS, and the survival time of patients in the low-risk group was longer than that of the high-risk group (*P* \< 0.001; [Fig. 3B](#fig-3){ref-type="fig"}).

![Risk score analysis of the differentially expressed lncRNA signature of cervical cancer.\
(A) Survival status and duration of cases. (B) Risk score of lncRNA signature; (C) Heatmap displaying low- and high-risk score groups for the two lncRNAs. The gray line represents the cut-off values for the high- and low-risk score groups.](peerj-07-6761-g002){#fig-2}

![The two differentially expressed lncRNA signature of cervical cancer for the outcome based on TCGA.\
(A) The two-lncRNA signature is shown by the time-dependent ROC curve for predicting 5-year survival. (B) The Kaplan--Meier curve of the risk score for the overall survival. (C) The expression level of lncRNAs between the low-risk and high-risk groups. \**P* \< 0.05.](peerj-07-6761-g003){#fig-3}
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###### Prognostic value of the differentially expressed lncRNAs by univariate and multivariate Cox regression analysis.
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  Variables          Estimate   StdErr   ChiSq   *P*                                     HR (95% CI)
  ------------------ ---------- -------- ------- --------------------------------------- ------------------------
  Univariate Cox                                                                         
  ILF3-AS1           −0.692     0.252    7.510   0.006[\*](#table-3fn2){ref-type="fn"}   0.501 \[0.305--0.821\]
  RASA4CP            −0.573     0.245    5.271   0.022[\*](#table-3fn2){ref-type="fn"}   0.570 \[0.352--0.921\]
  LINC00341          −0.483     0.242    3.975   0.046[\*](#table-3fn2){ref-type="fn"}   0.617 \[0.384--0.992\]
  AMZ2P1             −0.553     0.248    4.994   0.025[\*](#table-3fn2){ref-type="fn"}   0.575 \[0.354--0.934\]
  Multivariate Cox                                                                       
  ILF3-AS1           −0.703     0.253    7.742   0.005[\*](#table-3fn2){ref-type="fn"}   0.302 \[0.302--0.821\]
  RASA4CP            −0.576     0.245    5.514   0.019[\*](#table-3fn2){ref-type="fn"}   0.347 \[0.347--0.909\]

**Note:**

Estimate: β coefficient; HR, hazard ratio; CI, confidence interval.

*P* \< 0.05.

The prognostic value of the two-lncRNA signature and other clinical features
----------------------------------------------------------------------------

Based on the results of univariate Cox proportional hazard model analysis, some of the clinical features may predict poorer survival outcomes of CC patients ([Table 2](#table-2){ref-type="table"}). In addition, we further analyzed by the multivariate Cox proportional hazard model tumor status (*P* \< 0.001) and the risk score (*P* = 0.002), which were determined to be two independent prognostic factors of CC. The Kaplan--Meier curves of the aforementioned clinical features are shown in [Fig. S2](#supp-3){ref-type="supplementary-material"}. The results showed that clinical stage (*P* = 0.001), T stage (*P* \< 0.001), N stage (*P* \< 0.001), M stage (*P* = 0.011) and tumor status (*P* \< 0.001) were related to OS. We also evaluated the relationship between the risk score based on the differentially expressed two-lncRNA signature and the clinical features, and the risk score showed prognostic value for predicting the status of T stage (AUC = 0.607, *P* = 0.028; [Fig. S3](#supp-4){ref-type="supplementary-material"}). The expression levels of two differentially expressed lncRNAs in the low and high score groups in TCGA are shown in [Fig. 3C](#fig-3){ref-type="fig"}. The results revealed that the expression level of lncRNA RASA4CP was significantly different between the low-risk and high-risk groups (*P* \< 0.05).

qRT-PCR verification of the expression level of two lncRNAs in tissues and ROC curve analysis
---------------------------------------------------------------------------------------------

To confirm the expression levels of ILF3-AS1 and RASA4CP in CC, we analyzed their actual expression levels in 31 pairs of newly diagnosed CC clinical samples by qRT-PCR ([Table S1](#supp-5){ref-type="supplementary-material"}). The qRT-PCR results confirmed that the expression of the ILF3-AS1 and RASA4CP was downregulated, consistent with the TCGA results ([Fig. 4A](#fig-4){ref-type="fig"}). The actual expression levels of the two lncRNAs in the low-risk score and high-risk score groups in the clinical sample are shown in [Fig. 4B](#fig-4){ref-type="fig"}. To evaluate the specific diagnostic potential of ILF3-AS1 and RASA4CP, ROC curve analysis was performed. AUC values were 0.704 and 0.685 for ILF3-AS1 and RASA4CP, respectively, (*P* \< 0.05; [Figs. 4C](#fig-4){ref-type="fig"} and [4D](#fig-4){ref-type="fig"}). This indicates that each lncRNA could be an important biomarker for diagnosis of CC. However, the AUC value for both lncRNAs was 0.723, higher than that any single lncRNA alone (*P* \< 0.05; [Fig. 4E](#fig-4){ref-type="fig"}), suggesting improved diagnostic efficiency using the two-lncRNA signature.

![Analysis of expression of ILF3-AS1 and RASA4CP in clinical samples with qRT-PCR.\
(A) Quantitative RT-PCR validation of differentially expressed two lncRNAs (Comparison of fold change (2^−ΔΔCt^) of lncRNAs between TCGA results and qRT-PCR results). (B) The expression level of lncRNAs between the low-risk and high-risk groups based on qRT-PCR. (C, D and E) ROC curve analysis of specific two lncRNAs with relative expression level. (F) qRT-PCR validation of differentially expressed two lncRNAs (comparison of fold change (2^−ΔΔCt^) of lncRNAs between three cervical cancer cell lines results and one immortalized cervical epithelial cell line results).](peerj-07-6761-g004){#fig-4}

qRT-PCR verification of the two lncRNAs' expression in cervical cancer cell lines
---------------------------------------------------------------------------------

To detect ILF3-AS1 and RASA4CP expression in CC, we further examined gene expression pattern from three CC cell lines by qRT-PCR. Compared to the immortalized cervical epithelial cell line H8, expression of ILF3-AS1 and RASA4CP was downregulated in the human CC cell lines HeLa and SiHa, respectively. The expression pattern of the two lncRNAs is consistent with the TCGA results ([Fig. 4F](#fig-4){ref-type="fig"}).

Discussion
==========

With vaccination and early tumor screening programs, the incidence and mortality of CC have declined in recent decades. However, the incidence of CC in developing countries still remains high ([@ref-1]; [@ref-20]). The prognosis for CC patients would be improved if tumor development could be predicted in preclinical diagnosis. In recent years, non-coding RNAs in CC have been widely investigated ([@ref-4]; [@ref-27]), but most studies have mainly focused on the relationship and expression of mRNAs, miRNAs, genes and proteins ([@ref-13]; [@ref-14]; [@ref-15]) in CC. At present, there is still a lack of specific and effective biomarkers for use in diagnosis, clinical therapy and prognostic applications. Therefore, there is an urgent need to identify potential and reliable prognostic biomarkers to predict CC outcomes.

Based on the large-scale datasets provided by the TCGA public database, a number of studies have evaluated the prognostic value of lncRNAs in various cancer types such as gastric cancer, lung cancer, colorectal cancer and breast cancer ([@ref-17]; [@ref-21]; [@ref-25]; [@ref-31]). A new study evaluating the prognostic value of miRNAs in CC ([@ref-28]) assessed the potential use of a three-miRNA (miR-3154, miR-7-3 and miR-600) expression signature as well as individual miRNAs as prognostic biomarkers of CC. Similarly, another study using Cox regression analysis showed that a three-miRNA signature (miR-200c, miR-145 and miR-218-1) signature could be used as an independent prognostic factor in CC ([@ref-12]). This analysis used the TCGA database; however, the relationships between prognosis and differentially expressed lncRNAs in CC patients using large-scale samples have not yet been comprehensively analyzed.

In our study, we defined lncRNAs that were significantly associated with survival by screening differentially expressed lncRNAs from the TCGA database and using a large sample of CC patients. First, based on RNA sequencing data from TCGA (*P* \< 0.05), the Cox regression model was used on 49 differentially expressed lncRNAs from 289 CC patients. Two lncRNAs (ILF3-AS1 and RASA4CP) were identified. Subsequently, we calculated the risk score by combining the expression of these two lncRNAs and investigated whether this two-lncRNA signature could be used to independently predict OS in CC patients. Our results have shown that the single marker efficacy was limited, but multiple markers may provide more effective information for the prediction of cancer patients' prognoses. In the present study we compared the clinical features and sequencing data to investigate the relationship between the two lncRNAs and CC patients' survival by performing a risk score assessment. To our knowledge, this study is the first to combine risk scores with information about lncRNAs from the TCGA data to assess the survival and prognosis of CC patients.

To date, one report has shown that in melanoma, upregulated ILF3-AS1 promotes cell migration, invasion and proliferation by negatively regulating miR-200b/a/429, which implies that ILF3-AS1 may be a potential prognostic biomarker and therapeutic target for melanoma ([@ref-3]). However, the role of this lncRNA in the onset of CC has not been reported. Similarly, the role of RASA4CP in cancer has not been explored. Dysregulation in signaling pathways may play a crucial role in CC pathogenesis and progression. In the future, we intend to further analyze the signaling pathways associated with these lncRNAs by performing mechanistic research.

We also performed cross-validation of our findings, with qRT-PCR of which the results were in agreement with those from TCGA. We tried to verify the expression of ILF3-AS1 and RASA4CP in a Chinese population sample using risk scores, but the results were not statistically significant, probably because of the small sample size. However, we could see that the qRT-PCR results had the same trend as the TCGA data. We used ROC curve analysis to determine the sensitivity and specificity of ILF3-AS1 and RASA4CP as key lncRNAs in the detection of CC. Each of the two lncRNAs showed diagnostic value when considered alone, but more importantly, the AUC of the combination of two lncRNAs was 0.723 (*P* \< 0.05). This value was greater than that of each lncRNA alone, suggesting that the combination of these two lncRNAs could improve the diagnostic efficacy in CC. While we believe our findings have important clinical value, there are still some limitations which should nonetheless be considered. First, our findings need validation over a longer follow-up time. Second, additional data from TCGA combined with further molecular investigations and more clinical samples are needed to verify our findings. Finally, the function of ILF3-AS1 and RASA4CP in CC need to be examined in future studies.

Conclusion
==========

In conclusion, this is the first time to our knowledge that the TCGA public database has been used to identify lncRNAs that are significantly associated with prognosis of CC. The two-lncRNA signature of ILF3-AS1 and RASA4CP may serve as a potential independent biomarker for predicting CC prognosis. However, future studies are necessary to further explore the function and mechanism of these lncRNAs in CC.
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###### LncRNA sequencing data of TCGA.
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###### Fig. S1. ROC curves of the two lncRNAs (ILF3-AS1 and RASA4CP) to distinguish cervical cancer tissue from adjacent normal tissues in TCGA.
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###### Fig. S2. The prognostic value of different clinical features for overall survival of cervical cancer patients in TCGA.
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###### Fig. S3. The predictive value of the risk score for clinical features.

ROC curve is predicting different clinical features in TCGA.
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Click here for additional data file.
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###### Table S1. Relative expression of lncRNAs in 31 pairs of cervical cancer tumor and non-tumor tissues.

###### 

Click here for additional data file.
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###### Table S2. The protein-protein interaction network of co-expressed genes.

Gene name and Pearson \|R\|
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Click here for additional data file.
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